Dr. Beiki-Ardakani's areas of research interest include brachytherapy; MRI-guided brachytherapy for gynecological and prostate cancers; eye plaque therapy; fluid marker development for image-guided brachytherapy; and quality assurance and control.
Intermediate dose-volume parameters and the development of late rectal toxicity after MRI-guided brachytherapy for locally advanced cervix cancer.
Brachytherapy. 2017 Jul 27;:
Prospective Study of Dynamic Contrast-Enhanced MRI, Diffusion-Weighted MRI, and FDG Positron Emission Tomography Imaging in Brachytherapy for Cervix Cancer.
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E296
A prospective study of DWI, DCE-MRI and FDG PET imaging for target delineation in brachytherapy for cervical cancer.
Radiother Oncol. 2016 Aug 12;
Dosimetric and late radiation toxicity comparison between iodine-125 brachytherapy and stereotactic radiation therapy for juxtapapillary choroidal melanoma.
Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):510-5
A comparison between ¹²⁵Iodine brachytherapy and stereotactic radiotherapy in the management of juxtapapillary choroidal melanoma.
Br J Ophthalmol. 2013 Mar;97(3):327-32
Med Phys. 2008 Oct;35(10):4318-23
Med Phys. 2004 Jul;31(7):1960-3